12:00 AM
 | 
Jun 11, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

GLV-1h68: Phase I data

Data from 27 patients in an open-label, U.K. Phase I trial showed that escalating doses of IV GL-ONC1 were well tolerated and produced 9 cases of stable disease - 1 at 48 weeks, 3 at 24 weeks and 5 at 8-12 weeks....

Read the full 186 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >